Micell Technologies Inc. announced commercialization plans for its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES). In support of this strategy, the company has entered into a five-year agreement with Stentys as an exclusive worldwide distributor of the MiStent SES, except in the United States, Canada, China, South Korea and Japan. Stentys plans to launch MiStent in the first half of 2015 in Europe, followed by many other geographies where they have built a commercial network